Article
A phase II study of dual immune checkpoint blockade (ICB) plus androgen receptor (AR) blockade to enhance thymic T-cell production and immunotherapy response in metastatic breast cancer (MBC).
Journal of Clinical Oncology
(2019)
Disciplines
Publication Date
May 20, 2019
DOI
10.1200/JCO.2019.37.15_SUPPL.TPS1106
Citation Information
David B. Page, Isaac K Kim, Brie Chun, William L Redmond, et al.. "A phase II study of dual immune checkpoint blockade (ICB) plus androgen receptor (AR) blockade to enhance thymic T-cell production and immunotherapy response in metastatic breast cancer (MBC)." Journal of Clinical Oncology Vol. 37 (2019) Available at: http://works.bepress.com/walter-urba/287/